Role of FSP1 on Glioblastoma

Abstract

<p><strong><em>Objective</em></strong><strong>:</strong></p><p>To investigate the role of FSP1 on glioblastoma</p><p><strong><em>Method:</em></strong><br></p><p>Database search is first performed to look for any difference in the expression of FSP1 in glioblastoma, as well as the correlation between the expression and prognosis. The expression difference is then confirmed by western blot and RT-qPCR on human glioblastoma cell lines. Inhibition of FSP1 is done on the glioblastoma cell lines by using FSP1 inhibitor (iFSP1). Drug-induced cytotoxicity and cell proliferation are then checked via different assays (MTT, SRB) after treatment with iFSP1. Lipid peroxidation is used as a ferroptosis marker and is checked using lipid peroxidation assay.</p><p><strong><em>Result:</em></strong><br></p><p>The database search reveals there is an overexpression of FSP1 in GBM. FSP1 overexpression is also associated with poorer survival and worse outcomes in glioblastoma. Overexpression of FSP1 is then confirmed by western blot and RT-qPCR in different human glioblastoma cell lines. Cell proliferation is suppressed in human glioblastoma cell lines upon the addition of iFSP1. Cell viability is also decreased when compared to control.</p><p><strong><em>Conclusion:</em></strong><br></p><p>FSP1 overexpression is related to poorer survival and worse outcomes in glioblastoma. Inhibition of FSP1 increases suppression of cell proliferation and decreases cell viability in glioblastoma cell lines. Data suggests that the decrease in cell proliferation and viability may be due to ferroptosis.</p>